Avanir's multiple sclerosis drug fails in mid-stage trial
Dec 10 (Reuters) - Avanir Pharmaceuticals Inc said its drug used for the treatment of central neuropathic pain in patients with multiple sclerosis failed in a mid-stage trial, sending its shares down 18 percent in extended trading.
There was no difference between the treatment arms and placebo, the company said.
Avanir's shares were down 53 cents at $3.76 after the bell. (Reporting by Supantha Mukherjee in Bangalore; Editing by Maju Samuel)
- China food scandal spreads, drags in Starbucks, Burger King and McNuggets in Japan |
- U.S. court rulings create new uncertainty over Obamacare
- Israel pounds Gaza despite international peace efforts |
- EU readies possible capital, tech sanctions on Russia
- Train carrying MH17 bodies on final journey reaches Ukraine city |